Unity Biotechnology’s (UBX) “Buy” Rating Reaffirmed at Chardan Capital

Chardan Capital reissued their buy rating on shares of Unity Biotechnology (NASDAQ:UBX) in a research note published on Monday,Benzinga reports. They currently have a $6.00 price objective on the stock.

Separately, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Unity Biotechnology in a research note on Monday.

Unity Biotechnology Trading Down 4.8 %

Unity Biotechnology stock opened at $1.60 on Monday. Unity Biotechnology has a 1-year low of $0.94 and a 1-year high of $3.10. The firm has a market capitalization of $26.96 million, a price-to-earnings ratio of -1.22 and a beta of 1.02. The firm has a 50 day simple moving average of $1.84 and a 200 day simple moving average of $1.51.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Unity Biotechnology stock. Geode Capital Management LLC raised its position in Unity Biotechnology, Inc. (NASDAQ:UBX) by 9.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 163,242 shares of the company’s stock after purchasing an additional 14,199 shares during the period. Geode Capital Management LLC owned 0.97% of Unity Biotechnology worth $240,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 29.49% of the company’s stock.

About Unity Biotechnology

Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.